Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.54 |
| ▸ | CHKA | P35790 | 1/20 | 0.48 |
| ▸ | F10 | P00742 | 8/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL786057 | 0.98 | ROCK2 (0.53) | ROCK2ROCK1CHKAF10ADRB2 | |
| SCHEMBL3440166 | 0.90 | ROCK2 (0.49) | ROCK2ROCK1CHKAF10ADRB2 | |
| SCHEMBL786310 | 0.84 | CHKA (0.46) | ROCK2ROCK1CHKAF10ADRB2 | |
| SCHEMBL13083096 | 0.84 | F10 (0.47) | ROCK2ROCK1CHKAF10ADRB2 | |
| SCHEMBL15372697 | 0.83 | ADRB2 (0.49) | ROCK2ROCK1CHKAF10ADRB2 | |
| SCHEMBL10154050 | 0.83 | ADRA1D (0.51) | HRH3KDM1AL3MBTL1DRD2 | |
| SCHEMBL3440207 | 0.83 | CHKA (0.42) | ROCK2ROCK1CHKAF10ADRB2 | |
| SCHEMBL13059913 | 0.83 | CHKA (0.49) | ROCK2ROCK1CHKAF10ADRB2 | |
| SCHEMBL13139639 | 0.81 | DRD2 (0.43) | ROCK2ROCK1CHKAF10ADRB2 | |
| SCHEMBL12916521 | 0.81 | MEN1 (0.51) | ROCK2ROCK1SYKHRH3KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312542-A1 | HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-05 | — | — | US | disclosed |
| EP-4129402-A1 | HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2023-02-08 | — | — | EP | disclosed |
| CN-115298173-A | Hydroxypyrrolidine derivatives and medical use thereof | 田边三菱制药株式会社 | 2022-11-04 | — | — | CN | disclosed |
| US-20220298141-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-09-22 | — | — | US | disclosed |
| EP-4017849-A1 | ENZYME INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2022-06-29 | — | — | EP | disclosed |
| CN-114286820-A | Enzyme inhibitors | 卡尔维斯塔制药有限公司 | 2022-04-05 | — | — | CN | disclosed |
| WO-2021032934-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032934-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| EP-2188251-B1 | ARYLSULFONAMIDES WITH ANALGESIC ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2015-04-29 | — | — | EP | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-7858618-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-20100298288-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK & CO., INC (US) | 2010-11-25 | — | — | US | disclosed |
| US-20090137545-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137545-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| WO-2009021758-A1 | ARYLSULFONAMIDES HAVING AN ANALGESIC EFFECT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009021946-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| EP-2025675-A1 | Arylsulfonamides with analgetic activity | Boehringer Ingelheim International GmbH (DE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008022945-A1 | ARYL SULFONAMIDES WITH AN ANALGESIC ACTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1302462-A1 | SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137545-A1 | Compounds | ADORA2B, ABCB11, CYP11B1 | ROCK2 1744/4885ROCK1 913/4885CHKA 3194/4885 |
| US-20220298141-A1 | ENZYME INHIBITORS | SERPINB1, ACE, GAA | ROCK2 2516/4885ROCK1 1964/4885CHKA 2336/4885 |
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | SULT1E1, RRS1, SHH | ROCK2 1957/4885ROCK1 1323/4885CHKA 4648/4885 |
| US-20230312542-A1 | HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF | VHL, MDM2, NEDD4 | ROCK2 2701/4885ROCK1 2373/4885CHKA 4604/4885 |
| US-20100298288-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | CETP, APOB, MTTP | ROCK2 4474/4885ROCK1 4194/4885CHKA 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.